左旋多巴诱发异动症的病理生理机制及防治策略被引量：3

导出

摘要左旋多巴诱发异动症的作用机制目前仍未明了。本文综述了多巴胺受体的波动性刺激及突触后基因调控等机制,提出长效多巴胺制剂、多巴胺神经元保护剂、移植和神经营养因子以及干预或补偿突触后分子的改变等是阻止波动性刺激的形成、预防异动症发生的保护性策略。

作者徐岩

机构地区华中科技大学同济医学院附属协和医院神经科

出处《国外医学（神经病学．神经外科学分册）》 2002年第6期521-524,共4页 Foreign Medical Sciences（Section On Neurology & Neurosurgery）

关键词左旋多巴异动症病理生理机制防治策略药物不良反应

分类号 R742.5 [医药卫生—神经病学与精神病学]

引文网络
相关文献

参考文献17

1Zeng BY, Pearce RK, MacKenzie GM, et al. Alterations in preproenkephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with L-DOPA. EurJ Neurosci, 2000, 12(3): 1096-1104.
2Maratos EC, Jackson MJ, Pearce RK, et al. Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naive MPTP-lesioned common marmosets. Mov Disord, 2001, 16(4): 631-641.
3Calon F, Grondin R, Morisette M, et al. Molecular basis of levodopainduced dyskinesia. Ann Neurol, 2000, 47(suppl 1): S70-S78.
4Canales JJ, Graybiel AM. Patterns of gene expression and behavior induced by chronic dopamine treatments. Ann Neurol, 2000, 47(suppl 1): S53-S59.
5Morissette M, Grondin R, Goulet M, et al. Differential regulation of striatal preproenkephalin and preprotachykinin mRNA levels in MPTP-lesioned monkeys chronically treated with dopamine D1 or D2 receptor agonists. J Neurochem, 1999, 72(2): 682-692.
6Obese JA, Rodriguez-Oroz MC, Rodriguez M, et al. Pathophysiology of levodopa-induced dyskinesias in Pakinsion disease: Problems with the current model. Ann Nenrol, 2000, 47(suppl 1): S22-S34.
7Boraud T, Bezard E, Bioulac B, et al. Dopamine agonist-induceddyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurons in the MPTP-treated monkey. Brain, 2001, 124(3): 546-557.
8Calabresi P, Pisani A, Mercuri NB, et al. The corticostriatal projection: from synaptic plasticity to dysfunctions of the basal ganglia. Trends Neurosci, 1996, 19(1): 19-24.
9Calabresi P, Giacomini P, Bemardi G, Levadopa-induced dyskinesia: a pathological form of striatal synaptic plasticity? Ann Neurol, 2000, 47 (suppl 1): S60-S69.
10Masden CD, Olanow CW. Neuroprotection in Parkinson disease: the causes of Parkinson disease are being unraveled and rational neuroprotective therapoy is close to reality. Ann Neurol, 1998, 44(suppl 1): S189-S196.

同被引文献24

1Henry B,Crossman AR,Brotchie JM.Effect of repeated L-dopa,bromocriptine,or lisuide administration on preproenkephalin-A andpreproenkephalin-B mRNA levels in the striatum of the 6 hydroxydopamine-lesioned rat [ J ].Exp Neurol,1999,155(2):204-220.
2Van De Witte SV,Groenewegen HJ,Voorn P.MK801 alters the effects of priming with L-dopa on dopamine D1 receptor-induced changes in neuropeptide mRNA levels in the rat striatal output neurons[J].Synapse,2002,43(1):1-11.
3Quik M,Police S,Langston JW,et al.Increases in striatal preproenkephalin gene expression are associated with nigrostriatal damage but not L-DOPA-induced dyskinesias in the sqirrel monkey [ J ].Neuroscience,2002,113(1):213-220.
4Bibb JA,Chen JS,Taylor JR,et al.Effects of chronic exposure to cocaine are regulated by the neuronal protein Cdk5 [ J ].Nature,2001,410(6826):376-379.
5Oh JD,Vaughan CL,Chase TN.Effect of dopamine denervation and dopamine agonist administration on serine phosphorylation of striatal NMDA receptor subunits[ J].Brain Res,1999,821(1-2):433-442.
6Lee CS,Cenci MA,Schulzer M,et al.Embryonic ventral mesen cephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson disease [ J ].Brain,2000,123(7):1365-1379.
7Li YS,HayakawaK,HardyRR.The regulated expression of B lineage associated genes during B cell differentiation in bone marrow and fetal liver[J].J Exp Med,1993,178(3):951-960.
8Ida J,Llewellyn-Smith I J,Pivowsky P,et al.Retrograde tracers for light and electron microscopy[ M].In:Bolam JP eds.Experimental neuroanatomy:A practical approach.New York:Oxford U niversity Press,1992.31-59.
9Henry B,Fox SH,Crossman AR,et al.μ-and δ-opioid receptor antagonists reduced levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson disease[ J].Exp Neurol,2001,171(1):139-146.
10Nestler EJ,Kelz MB,Chen JS.ΔFosB:a molecular mediator of long-term neural and behavioral plasiticity[ J ].Brain Res,1999,835(1):10-17.